More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$20.96B
EPS
19.88
P/E ratio
39.5
Price to sales
6.48
Dividend yield
--
Beta
0.418111
Previous close
$159.73
Today's open
$159.02
Day's range
$155.79 - $160.64
52 week range
$149.18 - $479.79
show more
CEO
Yvonne L. Greenstreet
Employees
2500
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
133937576
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 9 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire • a day ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that wer.
Business Wire • Nov 10, 2026

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyop.
Business Wire • Nov 9, 2026

Brown Advisory Large-Cap Sustainable Growth Strategy Q3 2026 Holdings Performance
Consensus EPS estimates for 2026 and 2027 revised upward by an average of 6.0% and 4.3%, respectively, during the third quarter. Microsoft Corporation had one of its strongest quarterly stock performances since 1998. Snowflake's strong stock performance was driven by a third consecutive quarter of product revenue growth acceleration.
Seeking Alpha • Nov 6, 2026

Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth. "Today we announced two important decisions, both of which demonstrate our conviction in Alnylam's future," said Amy Schulman, Chair of Alnylam's Board of Directors. "Alnylam ha.
Business Wire • Nov 4, 2026

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London. A live audio webcast of the presentation will be available in the Investors section of the Company's website at www.alnylam.com/events. A replay will be posted on the website within 48 hours a.
Business Wire • Nov 4, 2026

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi.
Business Wire • Nov 3, 2026

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
Zacks Investment Research • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Alnylam Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.